Egfr T790m Mutation Positive Non Small Cell Lung Cancer Therapeutics
1. Tagrisso patent expiration
Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with...
TAGRISSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8946235 | ASTRAZENECA | 2-(2,4,5-substituted-anilino) pyrimidine compounds |
Aug, 2032
(6 years from now) | |
| US9732058 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(6 years from now) | |
| US11524951 | ASTRAZENECA | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
Jul, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12465608 | ASTRAZENECA | NA |
Nov, 2042
(16 years from now) | |
| US10183020 | ASTRAZENECA | Pharmaceutical compositions comprising AZD9291 |
Jan, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2020 |
| New Indication(I-774) | Apr 18, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 13, 2022 |
| Orphan Drug Exclusivity(ODE-102) | Nov 13, 2022 |
| New Indication(I-853) | Dec 18, 2023 |
| Orphan Drug Exclusivity(ODE-176) | Apr 18, 2025 |
| New Indication(I-941) | Feb 16, 2027 |
| New Indication(I-952) | Sep 25, 2027 |
| Orphan Drug Exclusivity(ODE-337) | Dec 18, 2027 |
Drugs and Companies using OSIMERTINIB MESYLATE ingredient
NCE-1 date: 14 November, 2019
Market Authorisation Date: 13 November, 2015
Dosage: TABLET
How can I launch a generic of TAGRISSO before it's drug patent expiration?
More Information on Dosage
TAGRISSO family patents
